EGFR and non-small cell lung carcinoma: Considering APE1 expression is not affected by E3330/Icotinib combinational treatment, these results provide support for the hypothesis that the redox activity of APE1 is critical for EMT in EGFR‐TKI‐resistant NSCLC cells.